Dry eye syndrome is a common disease of tear film and ocular surface developed in numerous aetiologies. Tear film instability and ocular surface disturbances that subsequently influence the tear film are among the primarily causes of this disease, but many other factors are involved in tear film disorders. Although eye surface is easily reached by classical ocular dosage forms, novel drug delivery systems for ocular administration offer advantages in terms of increased residence time on eye surface and/or controlled release of the drug, with enhanced therapeutic effectiveness. This book provides an overview on the potential benefits and limitations in dry eye syndrome management and reported successful formulations.

Novel strategies for ocular anti-inflammatory therapies are extensively being investigated to increase drug bioavailability and decrease adverse side effects of common treatments. Colloidal carriers based on lipid materials are becoming a suitable alternative due to several advantages, including solubilisation of hydrophobic/lipophilic anti-inflammatory drugs followed by bioavailability enhancement, modification of pharmacokinetic parameters, and protection of sensitive drugs from physical, chemical or biological degradation. This book presents and discusses data on the improvements being made in regards to novel drug delivery systems.